Financhill
Sell
43

NMTC Quote, Financials, Valuation and Earnings

Last price:
$1.07
Seasonality move :
-32.95%
Day range:
$1.01 - $1.09
52-week range:
$0.55 - $1.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.35x
P/B ratio:
11.36x
Volume:
86.6K
Avg. volume:
207K
1-year change:
0.93%
Market cap:
$33.3M
Revenue:
$3.5M
EPS (TTM):
-$0.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NMTC
NeuroOne Medical Technologies
-- -- 157.41% -57.14% --
NTRB
Nutriband
$710K -$0.13 -- -- $13.00
NVNO
enVVeno Medical
$400K -$0.30 -- -26.67% $16.50
SINT
SINTX Technologies
$586K -$5.29 20.07% -96.14% $300.00
XAIR
Beyond Air
$2.1M -- 195.4% -- $2.25
ZBH
Zimmer Biomet Holdings
$2B $2.04 0.26% 110.69% $121.85
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NMTC
NeuroOne Medical Technologies
$1.08 -- $33.3M -- $0.00 0% 5.35x
NTRB
Nutriband
$6.20 $13.00 $68.9M -- $0.00 0% 30.39x
NVNO
enVVeno Medical
$2.89 $16.50 $50.7M -- $0.00 0% 265.31x
SINT
SINTX Technologies
$3.42 $300.00 $4.6M -- $0.00 0% 0.94x
XAIR
Beyond Air
$0.27 $2.25 $23.7M -- $0.00 0% 4.85x
ZBH
Zimmer Biomet Holdings
$109.97 $121.85 $21.9B 24.71x $0.24 0.87% 2.92x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NMTC
NeuroOne Medical Technologies
-- -2.513 -- 2.23x
NTRB
Nutriband
1.68% 4.975 0.28% 4.65x
NVNO
enVVeno Medical
-- -0.506 -- --
SINT
SINTX Technologies
2.35% -1.062 3.06% 2.48x
XAIR
Beyond Air
0.34% 1.443 0.22% 2.15x
ZBH
Zimmer Biomet Holdings
33.23% 0.939 29.49% 0.82x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NMTC
NeuroOne Medical Technologies
$1.9M $1.7M -238.93% -238.93% 64.45% $183.6K
NTRB
Nutriband
$191K -$1.4M -65.19% -69.58% -210.38% -$1.1M
NVNO
enVVeno Medical
-- -$6.7M -- -- -- -$5.1M
SINT
SINTX Technologies
$157K -$2M -130.78% -132.95% -1697.55% -$2.6M
XAIR
Beyond Air
-$215K -$11M -151.32% -225.36% -1192.54% -$8.3M
ZBH
Zimmer Biomet Holdings
$1.4B $423.5M 4.87% 7.21% 17.34% $421.4M

NeuroOne Medical Technologies vs. Competitors

  • Which has Higher Returns NMTC or NTRB?

    Nutriband has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -211%. NeuroOne Medical Technologies's return on equity of -238.93% beat Nutriband's return on equity of -69.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    NMTC
    NeuroOne Medical Technologies
    58.85% $0.06 $2.9M
    NTRB
    Nutriband
    29.58% -$0.12 $11.4M
  • What do Analysts Say About NMTC or NTRB?

    NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 85.19%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 109.68%. Given that Nutriband has higher upside potential than NeuroOne Medical Technologies, analysts believe Nutriband is more attractive than NeuroOne Medical Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    NMTC
    NeuroOne Medical Technologies
    0 0 0
    NTRB
    Nutriband
    1 0 0
  • Is NMTC or NTRB More Risky?

    NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison Nutriband has a beta of 0.695, suggesting its less volatile than the S&P 500 by 30.457%.

  • Which is a Better Dividend Stock NMTC or NTRB?

    NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NMTC or NTRB?

    NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than Nutriband quarterly revenues of $645.8K. NeuroOne Medical Technologies's net income of $1.8M is higher than Nutriband's net income of -$1.4M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.35x versus 30.39x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NMTC
    NeuroOne Medical Technologies
    5.35x -- $3.3M $1.8M
    NTRB
    Nutriband
    30.39x -- $645.8K -$1.4M
  • Which has Higher Returns NMTC or NVNO?

    enVVeno Medical has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of --. NeuroOne Medical Technologies's return on equity of -238.93% beat enVVeno Medical's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NMTC
    NeuroOne Medical Technologies
    58.85% $0.06 $2.9M
    NVNO
    enVVeno Medical
    -- -$0.30 --
  • What do Analysts Say About NMTC or NVNO?

    NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 85.19%. On the other hand enVVeno Medical has an analysts' consensus of $16.50 which suggests that it could grow by 470.93%. Given that enVVeno Medical has higher upside potential than NeuroOne Medical Technologies, analysts believe enVVeno Medical is more attractive than NeuroOne Medical Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    NMTC
    NeuroOne Medical Technologies
    0 0 0
    NVNO
    enVVeno Medical
    1 0 0
  • Is NMTC or NVNO More Risky?

    NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.377, suggesting its more volatile than the S&P 500 by 37.658%.

  • Which is a Better Dividend Stock NMTC or NVNO?

    NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NMTC or NVNO?

    NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than enVVeno Medical quarterly revenues of --. NeuroOne Medical Technologies's net income of $1.8M is higher than enVVeno Medical's net income of -$6.2M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.35x versus 265.31x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NMTC
    NeuroOne Medical Technologies
    5.35x -- $3.3M $1.8M
    NVNO
    enVVeno Medical
    265.31x -- -- -$6.2M
  • Which has Higher Returns NMTC or SINT?

    SINTX Technologies has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -1700%. NeuroOne Medical Technologies's return on equity of -238.93% beat SINTX Technologies's return on equity of -132.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    NMTC
    NeuroOne Medical Technologies
    58.85% $0.06 $2.9M
    SINT
    SINTX Technologies
    42.78% -$6.96 $5.7M
  • What do Analysts Say About NMTC or SINT?

    NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 85.19%. On the other hand SINTX Technologies has an analysts' consensus of $300.00 which suggests that it could grow by 1946.78%. Given that SINTX Technologies has higher upside potential than NeuroOne Medical Technologies, analysts believe SINTX Technologies is more attractive than NeuroOne Medical Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    NMTC
    NeuroOne Medical Technologies
    0 0 0
    SINT
    SINTX Technologies
    0 1 0
  • Is NMTC or SINT More Risky?

    NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.201, suggesting its more volatile than the S&P 500 by 20.05%.

  • Which is a Better Dividend Stock NMTC or SINT?

    NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NMTC or SINT?

    NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than SINTX Technologies quarterly revenues of $367K. NeuroOne Medical Technologies's net income of $1.8M is higher than SINTX Technologies's net income of -$6.2M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.35x versus 0.94x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NMTC
    NeuroOne Medical Technologies
    5.35x -- $3.3M $1.8M
    SINT
    SINTX Technologies
    0.94x -- $367K -$6.2M
  • Which has Higher Returns NMTC or XAIR?

    Beyond Air has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -1215.67%. NeuroOne Medical Technologies's return on equity of -238.93% beat Beyond Air's return on equity of -225.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    NMTC
    NeuroOne Medical Technologies
    58.85% $0.06 $2.9M
    XAIR
    Beyond Air
    -20.06% -$0.15 $18.4M
  • What do Analysts Say About NMTC or XAIR?

    NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 85.19%. On the other hand Beyond Air has an analysts' consensus of $2.25 which suggests that it could grow by 736.74%. Given that Beyond Air has higher upside potential than NeuroOne Medical Technologies, analysts believe Beyond Air is more attractive than NeuroOne Medical Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    NMTC
    NeuroOne Medical Technologies
    0 0 0
    XAIR
    Beyond Air
    1 1 0
  • Is NMTC or XAIR More Risky?

    NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison Beyond Air has a beta of 0.160, suggesting its less volatile than the S&P 500 by 83.96%.

  • Which is a Better Dividend Stock NMTC or XAIR?

    NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NMTC or XAIR?

    NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than Beyond Air quarterly revenues of $1.1M. NeuroOne Medical Technologies's net income of $1.8M is higher than Beyond Air's net income of -$13M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.35x versus 4.85x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NMTC
    NeuroOne Medical Technologies
    5.35x -- $3.3M $1.8M
    XAIR
    Beyond Air
    4.85x -- $1.1M -$13M
  • Which has Higher Returns NMTC or ZBH?

    Zimmer Biomet Holdings has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of 11.84%. NeuroOne Medical Technologies's return on equity of -238.93% beat Zimmer Biomet Holdings's return on equity of 7.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    NMTC
    NeuroOne Medical Technologies
    58.85% $0.06 $2.9M
    ZBH
    Zimmer Biomet Holdings
    71% $1.20 $18.7B
  • What do Analysts Say About NMTC or ZBH?

    NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 85.19%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $121.85 which suggests that it could grow by 10.8%. Given that NeuroOne Medical Technologies has higher upside potential than Zimmer Biomet Holdings, analysts believe NeuroOne Medical Technologies is more attractive than Zimmer Biomet Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    NMTC
    NeuroOne Medical Technologies
    0 0 0
    ZBH
    Zimmer Biomet Holdings
    5 17 1
  • Is NMTC or ZBH More Risky?

    NeuroOne Medical Technologies has a beta of 0.659, which suggesting that the stock is 34.118% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.696%.

  • Which is a Better Dividend Stock NMTC or ZBH?

    NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings offers a yield of 0.87% to investors and pays a quarterly dividend of $0.24 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NMTC or ZBH?

    NeuroOne Medical Technologies quarterly revenues are $3.3M, which are smaller than Zimmer Biomet Holdings quarterly revenues of $2B. NeuroOne Medical Technologies's net income of $1.8M is lower than Zimmer Biomet Holdings's net income of $239.5M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Zimmer Biomet Holdings's PE ratio is 24.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 5.35x versus 2.92x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NMTC
    NeuroOne Medical Technologies
    5.35x -- $3.3M $1.8M
    ZBH
    Zimmer Biomet Holdings
    2.92x 24.71x $2B $239.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock